Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 624 of 6351
-
Can a new injection tame overactive blood cell production?
Disease control Recruiting nowThis is a multicenter, open-label Phase I clinical trial of BEBT-507 in subjects with polycythemia vera(PV). Phase Ia is a single-agent dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of BEBT-5…
Phase 1 • Sponsor: BeBetter Med Inc • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
Symptom relief Recruiting nowThis is a prospective, randomized, open-label, two-arm phase 2 trial that will evaluate whether the use of Pulsed Low-Dose-Rate radiation technique, as compared to standard radiation, is associated with reduced rates of clinically significant esophagitis during and following chem…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough blood cancers
Disease control Recruiting nowThis study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prio…
Phase 1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Gene therapy breakthrough for rare kidney disease enters human trials
Disease control Recruiting nowThe goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In …
Phase 1/2 • Sponsor: Arbor Biotechnologies • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could combining malaria vaccine with seasonal prevention save more kids?
Prevention Recruiting nowThis is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, amon…
Phase 4 • Sponsor: Epicentre • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on tough ovarian cancer in first human trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time tre…
Phase 1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a common stroke drug speed up brain bleed recovery?
Disease control Recruiting nowIntracerebral hemorrhage (ICH) is a dangerous form of stroke with high mortality rate. Other than evacuating the hematoma with surgical procedures, there is no current effective internal medicine treatment. Currently, there are many novel internal medicine treatment under develop…
Phase 2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
88% of patients with asthma and nasal polyps achieve dual remission on dupilumab
Disease control CompletedBackground: "Remission" is a primary therapeutic goal in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), though definitions vary regarding olfactory function. We evaluated "Dual Remission" kinetics in patients treated with dupilumab over 24 months. Methods: T…
Sponsor: Azienda Ulss 2 Marca Trevigiana • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New program aims to help men with HIV in fishing communities cut alcohol and boost treatment success
Disease control Recruiting nowThe investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in "risk environments" such as fishing comm…
Sponsor: San Diego State University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Gene therapy injection into the brain aims to treat rare genetic disorder
Disease control OngoingThis is an open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of RB001 administered via intracerebroventricular (ICV) injection in pediatric with SHANK3 related Phelan-McDermid Syndrome. Clinical data will be evaluated f…
Phase 1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New immunotherapy combo aims to tackle tough lung cancer
Disease control OngoingThis study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small …
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
A wearable ankle robot may boost walking recovery after stroke
Disease control By invitation onlyThe goal of this pilot clinical trial is to test whether training with a portable ankle robot improves ankle push-off and walking speed in adults with chronic stroke who have ankle weakness. The study will also evaluate whether the device is safe and practical to use during walki…
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill shows promise for severe postpartum depression in phase 3 trial
Symptom relief CompletedThe purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what sid…
Phase 3 • Sponsor: Lipocine Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Can a wearable patch steady aging bodies?
Prevention By invitation onlyThis study evaluates whether a drug-free, non-invasive haptic patch (LIBERTY Patch) affects fall-risk classification and balance/mobility confidence in adults ages 55 to 85. Approximately 150 participants are assigned to wear either the active LIBERTY Patch or a visually identica…
Sponsor: SuperPatch Limited LLC • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
New device sucks blood clots from lungs in acute PE trial
Disease control Recruiting nowTo evaluate the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary embolism.
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can the right dose and timing of steroids save more lives in ARDS?
Disease control Recruiting nowThe early phase of Acute Respiratory Distress Syndrome (ARDS) is characterized by intense alveolar inflammation. Corticosteroids have been used to treat ARDS for decades. Although their efficacy has been a subject of ongoing controversy, recent clinical practice guidelines for AR…
Phase 4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a wearable sensor replace fingerstick tests in the ICU?
Disease control CompletedHigh blood glucose levels (hyperglycaemia) are very common in patients admitted to intensive care units (ICUs) and are associated with worse health outcomes. Traditionally, glucose levels in critically ill patients are monitored using point-of-care blood glucose (POC-G) testing (…
Sponsor: Institut d'Investigacions Biomèdiques August Pi i Sunyer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
AI eye on the brain: a smarter scan for multiple sclerosis?
Diagnosis Recruiting nowMultiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS). It is also essential to monitor the treatment to see if it is working and to switch treatments if needed. Magnet…
Sponsor: Queen Mary University of London • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a simple score predict snakebite danger?
Knowledge-focused Recruiting nowIndia reports \~58,000 snakebite deaths/year, over 50% of global mortality. Clinical outcomes of antivenom may vary due to regional venom differences, delayed access to care, ineffective use of existing polyvalent antivenom. There is a need for an India-specific severity assessme…
Sponsor: Jubilee Mission Medical College and Research Institute • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose select…
Phase 2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC